| Phase 14 trials |
|
Phase 1
|
NCT06810583 |
May 2025 → Sep 2030 expected |
acute myeloid leukemia, childhood acute lymphoblastic leukemia |
St. Jude Children's Research Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT02688790 |
Apr 2016 → Apr 2019 |
bacterial infectious disease |
AbbVie |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT01946568 |
Jun 2013 → Apr 2015 |
bacterial infectious disease |
Durata Therapeutics Inc., an affiliate of Allergan plc |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT00678106 |
Sep 2008 → Jul 2009 |
bacterial infectious disease |
Pfizer |
Completed
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT04775953 |
Apr 2021 → Oct 2023 |
staphylococcal infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03091439 |
May → Aug 2017 |
osteomyelitis |
Allergan |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT03148756 |
May → Aug 2017 |
bacterial infectious disease, infective endocarditis |
AbbVie |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT02685033 |
Mar 2016 → Dec 2017 |
osteomyelitis |
Durata Therapeutics Inc., an affiliate of Allergan plc |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00057369 |
Feb 2001 → Jun 2003 |
bacterial infectious disease |
Vicuron Pharmaceuticals |
Unknown
|
No outcome recorded
|
| Phase 2/31 trial |
|
Phase 2/3
|
NCT04847921 |
Apr 2021 → Oct 2023 |
gram-positive bacterial infections, substance abuse |
University of Colorado, Denver |
Terminated
|
No outcome recorded
|
| Phase 37 trials |
|
Phase 3
|
NCT05117398 |
Jun 2023 → Sep 2025 overdue |
bacterial infectious disease with sepsis, staphylococcus aureus infection |
Assistance Publique - Hôpitaux de Paris |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT02814916 |
Mar 2017 → Jan 2024 |
methicillin-resistant staphylococcus aureus infectious disease |
AbbVie |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT02344511 |
Mar 2016 → Oct 2018 |
osteomyelitis |
Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) |
Withdrawn
|
No outcome recorded
|
|
Phase 3
|
NCT02269644 |
Nov 2015 → Nov 2016 |
— |
Durata Therapeutics Inc., an affiliate of Allergan plc |
Withdrawn
|
No outcome recorded
|
|
Phase 3
|
NCT02127970 |
Apr 2014 → Mar 2015 |
abscess, cellulitis, skin infection |
Durata Therapeutics Inc., an affiliate of Allergan plc |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT01431339 |
Jul 2011 → Nov 2012 |
abscess, cellulitis, skin infection |
Durata Therapeutics Inc., an affiliate of Allergan plc |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT01339091 |
Mar 2011 → Sep 2012 |
abscess, cellulitis, skin infection |
Durata Therapeutics Inc., an affiliate of Allergan plc |
Completed
|
No outcome recorded
|
| Phase 43 trials |
|
Phase 4
|
NCT06266494 |
Mar 2024 → May 2026 overdue |
— |
University of Colorado, Denver |
Recruiting
|
No outcome recorded
|
|
Phase 4
|
NCT03982030 |
Apr 2023 → Apr 2025 |
gram-positive bacterial infections |
Wake Forest University Health Sciences |
Withdrawn
|
No outcome recorded
|
|
Phase 4
|
NCT03426761 |
Jan 2018 → Dec 2022 |
osteomyelitis, periprosthetic joint infection |
Infectious Diseases Physicians, Inc. |
Completed
|
No outcome recorded
|
| Phase not applicable1 trial |
| — |
NCT05046860 |
Mar 2022 → Aug 2026 overdue |
periprosthetic joint infection |
Centre Hospitalier Universitaire de Nice |
Active not recruiting
|
No outcome recorded
|